GateHouse Bio (fka sRNAlytics)
We believe there is an RNA code that drives every disease
Founded 2016 · $5.7M raised
- Employees
- 11–50
- Founded
- 2016
- Business Model
- B2B
- Website
- gatehousebio.com
- Total Funding
- $5.7M
- Last Round
- $5.5M Series AApr 2018
- Rounds
- 2
About
GateHouse Bio is a TechBio company that uses AI to decode small RNA (sRNA) isoforms and develop biomarker-guided precision oligonucleotide therapeutics. Its proprietary Code-Breaker™ platform digitally designs targeted therapies for pulmonary, cardiac, neurological, and autoimmune diseases. The company seeks research collaborators, biopharma partners, and investors to advance its lead programs into human clinical trials.
Summary
GateHouse Bio (fka sRNAlytics) is a company, founded in 2016. It has raised $5.7M in total across 2 rounds, most recently a $5.5M Series A round in Apr 2018. Investors include SOSV, IndieBio and Claritas Capital.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Apr 2018
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
